Literature DB >> 21889186

Biological and clinical significance of NAC1 expression in cervical carcinomas: a comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas.

Shamima Yeasmin1, Kentaro Nakayama, Mohammed Tanjimur Rahman, Munmun Rahman, Masako Ishikawa, Atsuko Katagiri, Kouji Iida, Naomi Nakayama, Yoshiro Otuski, Hiroshi Kobayashi, Satoru Nakayama, Kohji Miyazaki.   

Abstract

This study examined the biological and clinical significance of NAC1 (nucleus accumbens associated 1) expression in both cervical squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas. Using immunohistochemistry, the frequency of positive NAC1 expression in adenocarcinomas/adenosquamous carcinomas (31.0%; 18/58) was significantly higher than that in squamous cell carcinomas (16.2%; 12/74) (P = .043). NAC1 gene amplification was identified by fluorescence in situ hybridization in 5 (7.2%) of 69 squamous cell carcinomas. NAC1 amplification was not identified in the adenocarcinomas (0%; 0/58). Positive NAC1 expression was significantly correlated with shorter overall survival in squamous cell carcinomas (P < .0001). A multivariate analysis showed that positive NAC1 expression in squamous cell carcinomas was an independent prognostic factor for overall survival after standard radiotherapy (P = .0003). In contrast to squamous cell carcinomas, positive NAC1 expression did not correlate with shorter overall survival in adenocarcinomas/adenosquamous carcinomas (P = .317). Profound growth inhibition, increased apoptosis, decreased cell proliferation, and decreased cell migration and invasion were observed in silencing RNA-treated cancer cells with NAC1 overexpression compared with cancer cells without NAC1 expression. NAC1 overexpression stimulated proliferation, migration, and invasion in the cervical cancer cell lines TCS and Hela P3, which normally lack NAC1 expression. These findings indicate that NAC1 overexpression is critical to the growth and survival of cervical carcinomas irrespective of histologic type. Furthermore, they suggest that NAC1 silencing RNA-induced phenotypes depend on the expression status of the targeted cell line. Therefore, cervical carcinoma patients with NAC1 expression may benefit from a targeted therapy irrespective of histologic type. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889186     DOI: 10.1016/j.humpath.2011.05.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

1.  Identification of the NAC1-regulated genes in ovarian cancer.

Authors:  Min Gao; Ren-Chin Wu; Alice L Herlinger; Kailee Yap; Jung-Won Kim; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2013-11-06       Impact factor: 4.307

2.  Identification of a small-molecule compound that inhibits homodimerization of oncogenic NAC1 protein and sensitizes cancer cells to anticancer agents.

Authors:  XiaoHui Wang; Cheng Ji; HongHan Zhang; Yu Shan; YiJie Ren; YanWei Hu; LiangRong Shi; LingChuan Guo; WeiDong Zhu; YuJuan Xia; BeiJia Liu; ZiYun Rong; BiLian Wu; ZhiJun Ming; XingCong Ren; JianXun Song; JinMing Yang; Yi Zhang
Journal:  J Biol Chem       Date:  2019-05-17       Impact factor: 5.157

3.  Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis.

Authors:  Yibing Fan; Juan Chen
Journal:  Bioengineered       Date:  2017-01-04       Impact factor: 3.269

4.  Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.

Authors:  Sultana Razia; Kentaro Nakayama; Kohei Nakamura; Tomoka Ishibashi; Masako Ishikawa; Toshiko Minamoto; Kouji Iida; Yoshiro Otsuki; Satoru Nakayama; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Exp Ther Med       Date:  2019-07-12       Impact factor: 2.447

5.  NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells.

Authors:  Kai Lee Yap; Stephanie I Fraley; Michelle M Thiaville; Natini Jinawath; Kentaro Nakayama; Jianlong Wang; Tian-Li Wang; Denis Wirtz; Ie-Ming Shih
Journal:  Cancer Res       Date:  2012-07-03       Impact factor: 12.701

Review 6.  Protein mislocalization: mechanisms, functions and clinical applications in cancer.

Authors:  Xiaohong Wang; Shulin Li
Journal:  Biochim Biophys Acta       Date:  2014-04-04

7.  MiR-361-3p alleviates cerebral ischemia-reperfusion injury by targeting NACC1 through the PINK1/Parkin pathway.

Authors:  Xihong Ye; Hua Song; Huimin Hu; Chunli Zhou; Qinyi Chen; Lin Hong; Min Huang; Hongfei Zhu
Journal:  J Mol Histol       Date:  2022-01-24       Impact factor: 2.611

8.  A Recurrent De Novo Variant in NACC1 Causes a Syndrome Characterized by Infantile Epilepsy, Cataracts, and Profound Developmental Delay.

Authors:  Kelly Schoch; Linyan Meng; Szabolcs Szelinger; David R Bearden; Asbjorg Stray-Pedersen; Oyvind L Busk; Nicholas Stong; Eriskay Liston; Ronald D Cohn; Fernando Scaglia; Jill A Rosenfeld; Jennifer Tarpinian; Cara M Skraban; Matthew A Deardorff; Jeremy N Friedman; Zeynep Coban Akdemir; Nicole Walley; Mohamad A Mikati; Peter G Kranz; Joan Jasien; Allyn McConkie-Rosell; Marie McDonald; Stephanie Burns Wechsler; Michael Freemark; Sujay Kansagra; Sharon Freedman; Deeksha Bali; Francisca Millan; Sherri Bale; Stanley F Nelson; Hane Lee; Naghmeh Dorrani; David B Goldstein; Rui Xiao; Yaping Yang; Jennifer E Posey; Julian A Martinez-Agosto; James R Lupski; Michael F Wangler; Vandana Shashi
Journal:  Am J Hum Genet       Date:  2017-01-26       Impact factor: 11.043

9.  ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.

Authors:  Zhou-lan Bai; Yan-yang Wang; Hong Zhe; Jian-li He; Ping Hai
Journal:  Radiat Oncol       Date:  2012-12-23       Impact factor: 3.481

10.  Loss of NAC1 expression is associated with defective bony patterning in the murine vertebral axis.

Authors:  Kai Lee Yap; Polina Sysa-Shah; Brad Bolon; Ren-Chin Wu; Min Gao; Alice L Herlinger; Fengying Wang; Francesco Faiola; David Huso; Kathleen Gabrielson; Tian-Li Wang; Jianlong Wang; Ie-Ming Shih
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.